Quantum Biopharma (QNTM) Asset Writedowns and Impairment (2020 - 2023)

Quantum Biopharma (QNTM) reported Asset Writedowns and Impairment of $236186.0 for Q4 2023, down 93.85% sequentially from $3.8 million in Q2 2023.

Quantum Biopharma (QNTM) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends

Quantum Biopharma (QNTM) has 2 years of Asset Writedowns and Impairment data on file, last reported at $236186.0 in Q4 2023.

For the quarter ending Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to $236186.0; the trailing twelve-month figure through Dec 2024 stood at $236186.0 (down 94.82% YoY), and the FY2023 full-year result was $4.6 million, changed N/A from the prior year.
Asset Writedowns and Impairment eased to $236186.0 in Q4 2023, from $3.8 million in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $3.8 million in Q2 2023 to a low of $22202.8 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,320.50 Bn	66,320.21 Bn	-
2	Nanobiotix	1,933.82 Bn	1,933.76 Bn	-
3	Akari Therapeutics	1,022.34 Bn	1,022.34 Bn	-
4	BeOne Medicines	472.93 Bn	468.14 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.22 Bn	114.98 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.96 Bn	61.21 Bn	3.31 Bn
7	Belite Bio	62.66 Bn	62.66 Bn	-
8	Argenx Se	56.07 Bn	50.89 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.60 Bn	34.59 Bn	959.66 Mn
10	Quantum Biopharma	12.93 Bn	12.93 Bn	-

Download Data